OCUL vs VTR · rev $24.3M vs P/E 149, rev $1.73B
Ocular Therapeutix Inc (OCUL) versus Ventas Inc (VTR) — a side-by-side from cached financials, not a winner call.
Ocular Therapeutix Inc (OCUL) is a biotechnology company listed on US.
Ventas Inc (VTR) is a reit - healthcare facilities company listed on NYSE.
Latest reported OCUL revenue for 2026-06-30 was $24.3M. Net income was -$167.4M. OCUL currently screens at market cap $1.76B.
Latest reported VTR revenue for 2026-06-30 was $1.73B. Net income was $72.2M. Revenue was up 4.4% from 2026-03-31 to 2026-06-30. VTR currently screens at market cap $39.94B and trailing P/E 149.4.
OCUL currently screens at market cap $1.76B. VTR currently screens at market cap $39.94B and trailing P/E 149.4.
Not investment advice. Open the OCUL and VTR stock pages for the full models.
Not investment advice.